More delay in Sputnik V roll-out in Delhi-NCR

Indraprastha Apollo had earlier said that it would tentatively start administering the two-dose vaccine by June 25.

June 27, 2021 02:05 pm | Updated 02:25 pm IST - New Delhi

A flight carrying 56.6 MT shipment of Sputnik V vaccines. File

A flight carrying 56.6 MT shipment of Sputnik V vaccines. File

The roll-out of Russian COVID-19 vaccine Sputnik V at various private hospitals in the Delhi-NCR region has been delayed again, officials said on Sunday.

"We do not have a clarity on the dates of the vaccine roll-out," a spokesman of Apollo Hospitals said.

Indraprastha Apollo herehad earlier said that it would tentatively start administering the two-dose vaccine by June 25.

An official of Madhukar Rainbow Children's Hospital said thefacility has also not received Sputnik V doses so far fromHyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country. "There is a delay on the part of the suppliers. They have not shared any specific reason for it. I think it could be related to the supply of both the doses together," he said.

SputnikV uses two different viruses that cause the common cold (adenovirus) in humans.The two doses, given 21 days apart, are different and not interchangeable.

Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.

The Centre has fixed the price of the vaccine at ₹1,145 per dose. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at ₹780 per dose, while that of Covaxin at ₹1,410 per dose.

Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed the vaccine and the Russian Direct Investment Fund (RDIF) is marketing it globally.

Dr Reddy's Laboratories has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India. According to Gamaleya and the RDIF,SputnikVhas demonstrated an efficacy rate of 92 per cent.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.